SG11201909322VA - Treatment of asthma with anti-tslp antibody - Google Patents
Treatment of asthma with anti-tslp antibodyInfo
- Publication number
- SG11201909322VA SG11201909322VA SG11201909322VA SG11201909322VA SG 11201909322V A SG11201909322V A SG 11201909322VA SG 11201909322V A SG11201909322V A SG 11201909322VA SG 11201909322V A SG11201909322V A SG 11201909322VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- asthma
- pct
- medlmmune
- tslp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484864P | 2017-04-12 | 2017-04-12 | |
| US201762553477P | 2017-09-01 | 2017-09-01 | |
| US201762553575P | 2017-09-01 | 2017-09-01 | |
| PCT/US2018/027271 WO2018191479A1 (en) | 2017-04-12 | 2018-04-12 | Treatment of asthma with anti-tslp antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909322VA true SG11201909322VA (en) | 2019-11-28 |
Family
ID=62092313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909322V SG11201909322VA (en) | 2017-04-12 | 2018-04-12 | Treatment of asthma with anti-tslp antibody |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10828365B2 (ar) |
| EP (1) | EP3609917A1 (ar) |
| JP (2) | JP7330896B2 (ar) |
| KR (1) | KR20190140956A (ar) |
| CN (1) | CN110573525A (ar) |
| AU (1) | AU2018253118A1 (ar) |
| BR (1) | BR112019021482A2 (ar) |
| CA (1) | CA3059364A1 (ar) |
| CL (1) | CL2019002897A1 (ar) |
| CO (1) | CO2019011462A2 (ar) |
| IL (1) | IL269791B (ar) |
| JO (1) | JOP20190243A1 (ar) |
| MX (1) | MX2019012158A (ar) |
| PE (1) | PE20200484A1 (ar) |
| PH (1) | PH12019502331A1 (ar) |
| SG (1) | SG11201909322VA (ar) |
| TN (1) | TN2019000289A1 (ar) |
| TW (1) | TW201838652A (ar) |
| UY (1) | UY37676A (ar) |
| WO (1) | WO2018191479A1 (ar) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3347377T (lt) * | 2015-09-09 | 2021-05-25 | Novartis Ag | Užkrūčio liaukos stromos limfopoetiną (tslp) rišantys antikūnai ir antikūnų panaudojimo būdai |
| CN113853387B (zh) * | 2019-06-04 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 能结合胸腺基质淋巴细胞生成素的抗体及其应用 |
| EP3996747A4 (en) * | 2019-07-11 | 2023-08-16 | Tavotek Biotherapeutics (Hong Kong) Limited | AGENTS INTERFERING WITH THYMUS TROMIC LYMPHOPOIETIN (TSLP) RECEPTOR SIGNALING |
| US20220289833A1 (en) * | 2019-09-04 | 2022-09-15 | Biosion Inc. | Antibodies binding tslp and uses thereof |
| IL292437A (en) * | 2019-10-28 | 2022-06-01 | Medimmune Ltd | Dry powder formulations of antibodies that bind thymic lymphopoietin (tslp) and methods of using them |
| AU2020400221A1 (en) * | 2019-12-13 | 2022-05-19 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-TSLP antibody and uses thereof |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| WO2021163588A1 (en) * | 2020-02-13 | 2021-08-19 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
| KR20220140772A (ko) * | 2020-02-13 | 2022-10-18 | 암젠 인크 | 인간 항-tslp 항체 제형 및 염증성 질환의 치료 방법 |
| JP2023513833A (ja) * | 2020-02-18 | 2023-04-03 | アムジェン インコーポレイテッド | ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法 |
| WO2022117079A1 (zh) * | 2020-12-03 | 2022-06-09 | 江苏恒瑞医药股份有限公司 | 结合胸腺基质淋巴细胞生成素的抗体及其应用 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| CN116897053A (zh) * | 2021-03-03 | 2023-10-17 | 正大天晴药业集团股份有限公司 | 含抗tslp抗体的药物组合物 |
| TW202306982A (zh) * | 2021-04-19 | 2023-02-16 | 英商梅迪繆思有限公司 | 具有改善的穩定性的抗tslp fab |
| CR20230531A (es) | 2021-04-23 | 2024-01-08 | Amgen Inc | Composiciones de anticuerpos anti-tslp y usos de las mismas |
| JP2024516595A (ja) | 2021-04-23 | 2024-04-16 | アムジエン・インコーポレーテツド | 修飾された抗ｔｓｌｐ抗体 |
| CN113683694B (zh) * | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN117209604B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| WO2024092064A1 (en) | 2022-10-26 | 2024-05-02 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| CN117551195B (zh) * | 2024-01-12 | 2024-04-09 | 杭州畅溪制药有限公司 | 靶向tslp的vhh纳米抗体及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| MY162511A (en) | 2009-11-04 | 2017-06-15 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| AR082163A1 (es) * | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| WO2015061441A1 (en) * | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
| SG10201913611QA (en) * | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| BR112017019412A2 (pt) | 2015-03-11 | 2018-05-02 | Glaxosmithkline Ip Dev Ltd | proteínas ligadoras de tslp |
| US10000561B2 (en) | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
-
2017
- 2017-06-16 JO JOP/2019/0243A patent/JOP20190243A1/ar unknown
-
2018
- 2018-04-12 CN CN201880026131.3A patent/CN110573525A/zh active Pending
- 2018-04-12 IL IL269791A patent/IL269791B/en unknown
- 2018-04-12 PE PE2019002026A patent/PE20200484A1/es unknown
- 2018-04-12 TN TNP/2019/000289A patent/TN2019000289A1/en unknown
- 2018-04-12 EP EP18721605.6A patent/EP3609917A1/en active Pending
- 2018-04-12 SG SG11201909322V patent/SG11201909322VA/en unknown
- 2018-04-12 KR KR1020197033043A patent/KR20190140956A/ko active IP Right Grant
- 2018-04-12 AU AU2018253118A patent/AU2018253118A1/en active Pending
- 2018-04-12 US US15/951,602 patent/US10828365B2/en active Active
- 2018-04-12 CA CA3059364A patent/CA3059364A1/en active Pending
- 2018-04-12 MX MX2019012158A patent/MX2019012158A/es unknown
- 2018-04-12 UY UY0001037676A patent/UY37676A/es unknown
- 2018-04-12 BR BR112019021482-8A patent/BR112019021482A2/pt unknown
- 2018-04-12 TW TW107112622A patent/TW201838652A/zh unknown
- 2018-04-12 JP JP2019555854A patent/JP7330896B2/ja active Active
- 2018-04-12 WO PCT/US2018/027271 patent/WO2018191479A1/en unknown
-
2019
- 2019-10-11 CL CL2019002897A patent/CL2019002897A1/es unknown
- 2019-10-11 PH PH12019502331A patent/PH12019502331A1/en unknown
- 2019-10-16 CO CO2019011462A patent/CO2019011462A2/es unknown
-
2020
- 2020-11-09 US US17/093,387 patent/US20210052726A1/en active Pending
-
2023
- 2023-05-15 JP JP2023080295A patent/JP2023099233A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018191479A1 (en) | 2018-10-18 |
| JP7330896B2 (ja) | 2023-08-22 |
| US20180296669A1 (en) | 2018-10-18 |
| JP2020516647A (ja) | 2020-06-11 |
| CO2019011462A2 (es) | 2019-10-31 |
| KR20190140956A (ko) | 2019-12-20 |
| IL269791B (en) | 2022-07-01 |
| TN2019000289A1 (en) | 2021-05-07 |
| CA3059364A1 (en) | 2018-10-18 |
| MX2019012158A (es) | 2019-12-16 |
| US20210052726A1 (en) | 2021-02-25 |
| CN110573525A (zh) | 2019-12-13 |
| BR112019021482A2 (pt) | 2020-05-12 |
| EP3609917A1 (en) | 2020-02-19 |
| AU2018253118A1 (en) | 2019-10-24 |
| PH12019502331A1 (en) | 2020-09-28 |
| CL2019002897A1 (es) | 2020-03-06 |
| UY37676A (es) | 2018-10-31 |
| TW201838652A (zh) | 2018-11-01 |
| IL269791A (en) | 2019-11-28 |
| PE20200484A1 (es) | 2020-03-03 |
| US10828365B2 (en) | 2020-11-10 |
| JOP20190243A1 (ar) | 2019-10-13 |
| JP2023099233A (ja) | 2023-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201906933SA (en) | Functionalized erythroid cells | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201804528YA (en) | Multi-passenger ride vehicle | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201900634VA (en) | Chimeric antigen receptor | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201809993VA (en) | Oncolytic viruses comprising esrage and methods of treating cancer | |
| SG11201901203PA (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy |